Meet Tyler Trueg 1

tyler trueg project lead lilly coi

Tyler Trueg is a project lead on the Patients 2 Trials Consortium, a collaboration among Lilly, Novartis and Pfizer aimed at helping patients match to clinical trials. He joined Lilly as part of the Lilly’s Visiting Scientist Fellowship, a program which allows doctoral graduates the ability to experience the drug development process and apply their expertise in a focused area within the organization.

Tyler’s experience in pharmacy and business, along with a passion for technology and disruptive innovation makes him a great addition to the Lilly COI team. While he is a scientist at heart, his entrepreneurial spirit drives him to find new ways to bring the patient’s perspective into clinical trial design. His overall mission is to help clinical trial teams better connect with patients through the use of technology and community engagement. You can follow him on Twitter @tylertrueg.


Bringing Clinical Trials To the ePatient 1

patient and clinician looking at tablet, digital health, mobile health, epatient

hGraph: patient + clinician looking together by Kelly Mansfield is licensed under CC by 2.0

ePatients—patients who are well-informed and empowered by digital technology and see themselves as equal partners with their doctors and healthcare providers—are on their way to becoming more the norm than the exception. For example, according to a recent Pew Research study, 72 percent of Internet users said they had looked up health information in the past year.

Another often-quoted statistic about the current state of clinical trials tells us that only 16 percent of cancer patients surveyed are aware that clinical trials are an option. This could indicate that we are missing opportunities to increase awareness about clinical trials through digital technology and online resources. In a time where 30 percent of trials never get off the ground because they fail to enroll enough patients, we can’t afford to miss these opportunities any longer.  Bringing information about clinical trials to ePatients is important in expanding healthcare options and getting better treatments to the public faster.


Infographic: Preferences and Perceptions in Clinical Research 4

Last year, the Center for Information & Study on Clinical Research Participation (CISCRP) surveyed more than 5,700 people for an in-depth study on public and patient perceptions, motivations, and experiences with clinical research participation. The research showed the differences between where patients prefer to get their clinical trial information and where they actually get information about trials.

Many patients want to get information from their primary physician (52 percent) or their specialist (41 percent) but more people get their clinical trial information from the internet (46 percent) than from their primary physician or specialist (both 20 percent).


Listening, Engaging and Learning: Lilly Social Media 1

laptop and stethoscope by jfcherry (CC by SA)

laptop and stethoscope by jfcherry (CC by SA)

Earlier this year, we reached our 2nd anniversary on Twitter. When we first started out, we weren’t quite sure what to expect. We began with a foundational belief  “that drug development processes must improve, and that open innovation methods can be used to foster necessary changes.”

In order to have the conversations that would lead us down the path to developing more patient-friendly tools and resources for clinical trials, we figured that social media would be a good place to start. In the time since our first tweet, we’ve come to know people with a wide range of of experiences, perspectives and ideas when it comes to drug development. And, these ideas have had a significant impact on what we’re doing at Lilly COI today.

Our involvement in the online community is one of Lilly’s social media channels, which span a wide variety of platforms including blogs, Twitter, Facebook, Pinterest, Instagram and YouTube. Each has a different focus, but there is common high level intent—engage in public on important issues surrounding disease management and prevention, currently available medicines, and innovation towards the much-needed new medicines of tomorrow.

Here’s a brief overview of each of the channels within Lilly’s online network: